Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 32Active not recruiting 16Completed 4Not yet recruiting 2Withdrawn 1Terminated 1Available 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Breast 3Dermatologic 1

Conditions

Breast Neoplasms 3Melanoma 1

Interventions

pembrolizumab 68Cyclophosphamide 46Cisplatin 43Nivolumab 36Paclitaxel 33Carboplatin 31Radiotherapy 29Gemcitabine 28Docetaxel 25Dexamethasone 22atezolizumab 21Bevacizumab 20Doxorubicin 19Magnetic Resonance Spectroscopy 18Blood Specimen Collection 18Radiosurgery 17fludarabine 16Vincristine 16Lenalidomide 16Etoposide 16Letrozole 15Ipilimumab 15Fluorouracil 15palbociclib 14Surveys and Questionnaires 14Rituximab 14Radiation 14Leucovorin 14Cytarabine 14durvalumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × ribociclib × 90 days × Clear all
NCT06075758 2026-06-01

A Study of Ribociclib in Combination With Hormonal Therapy in HR+/HER2- Advanced or Metastatic Breast Cancer

Novartis

Completed
175 enrolled
Breast

Breast Neoplasms

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed
216 enrolled
Dermatologic

Melanoma

NCT04943497 2026-04-01

PROSPERITY

Novartis

Completed
2,424 enrolled
Breast

Breast Neoplasms

NCT07487129 2026-03-23

Clinical and P

Beni-Suef University

Phase 4 Completed
206 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡